Subcutaneous Botulinum Toxin for Cutaneous Allodynia.
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Allergan
- 03 May 2014 Status changed from active, no longer recruiting to completed.
- 03 May 2014 Primary endpoint 'Time-to-treatment-failure' has not been met.
- 03 May 2014 Results presented at the 33rd Annual Scientific Meeting of the American Pain Society.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History